IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Akihiro FUNAKOSHI et al.

Title: A PREVENTIVE OR THERAPEUTIC AGENT FOR PANCREATITIS

COMPRISING IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT

Appl. No.: 09/762,550

International 8/23/1999

Filing Date:

371(c) Date: 2/9/2001

Examiner: Lorraine Spector

Art Unit: 1647

Conf. No.: 5276

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of any of a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

Both G1 and G2 were previously submitted but, due to errors in the SB08, were not marked as considered.

An English abstract of foreign-language Document G1 is provided, which meets the concise explanation of relevance requirement for foreign language references. The absence of a full translation does not relieve the PTO from its duty to consider the submitted foreign language document (37 CFR §1.98 and MPEP §609). Document G1 was previously submitted as Document A6 cited in the IDS filed on May 9, 2001. The reference was not considered by the Examiner because no English translation was provided. Applicants submitted the English abstract with an Amendment filed on April 22, 2004. The reference was not indicated as considered by the Examiner.

Document G2 was submitted in the IDS filed on January 6, 2011, and the Examiner did not consider the reference, noting "no copy found." Applicants herein resubmit the reference, and have indicated that only a two page Abstract is provided.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

A credit card payment form in the amount of \$180.00 is enclosed to cover the fee associated with an information disclosure statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this submission under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a rejected credit card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date December 5, 2011

FOLEY & LARDNER LLP Customer Number: 22428

Telephone:

(202) 295-5569

Facsimile:

(202) 672-5399

Ву

Stephen B. Maebius Attorney for Applicant Registration No. 35,264